Shane Poplawski

Shane Poplawski is an accomplished scientist with extensive experience in assay development and next-generation sequencing (NGS) technologies. Currently serving as Director of Assay Development at DNA Electronics since July 2022, Shane leads a multi-disciplinary team in the development of an automated sample-to-answer NGS device. Previous roles include Principal Scientist at Volition, where Shane spearheaded an innovation team focused on epigenetic-based liquid biopsy techniques for early cancer detection, and a Staff Scientist at DNA Electronics, managing a PCR team for sepsis identification. Additionally, Shane has contributed to the development of nanopore sequencing techniques at the J. Craig Venter Institute and studied epigenomic changes at Abbott. Shane holds a PhD in Pharmacology from the University of Pennsylvania and a Bachelor of Science in Biochemistry from Canisius University.